RecruitingNCT07204392

Unveiling the Germline Predisposition to Myeloproliferative Neoplasms


Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Enrollment

313 participants

Start Date

Jun 27, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The classic Ph-negative myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic disorders caused by a dysregulated JAK/STAT signal transduction because of acquired somatic mutations of JAK2, CALR or MPL genes. They are sporadic diseases but there are several lines of evidence that support the role of germline factors in the pathogenesis of MPN: the existence of familial clustering, the presence of more than one clone in some patients, the known existence of common polymorphisms that cause predisposition to MPN. In this study, we would like to define the germline predisposition to MPN.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • A diagnosis of PV, ET, prePMF, overt PMF or MPN-U according to 2016 WHO criteria
  • Characterization of the MPN driver mutation performed at any moment before enrolment
  • diagnosis of MPN made when the patient was younger than 27 years old OR at least a second case of hematologic malignancies in first or second-degree relatives

Exclusion Criteria1

  • None

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Fondazione IRCCS Policlinico San Matteo

Pavia, Lombardy, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07204392


Related Trials